Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
They are FDA-approved for specific conditions, have controlled dosages, and cause minimal side effects
Analysis of commercial claims data covering approximately 50 million insured lives found GLP-1 users experienced: 44% fewer major cardiovascular-related hospitalizations 69% improvement in medical spend growth among diabetes-related GLP-1 users over 30 months 37% improvement in medical spend growth among weight-loss GLP-1 users over 18 months Researchers have also observed positive trends related to inflammatory conditions, cardiovascular disease, and other chronic health concerns
Discussion As the use of GLP-1 RAs continues to rise in the US for both diabetes and obesity management ( 1 , 2 ), understanding why patients discontinue these therapies is critical for improving long-term treatment outcomes
Not for therapeutic, diagnostic, or veterinary use.
US$ 25.11
US$ 29.59
US$ 26.95
US$ 23.64
